Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer’s stock surged up to 11 percent after the pharma giant reported a robust 85 percent year-on-year rise in net profit ...

Below is some historical data on the post-earnings performance of Pfizer stock compared to the stock performance of peers that reported their earnings just before Pfizer. For a fair comparison ...

Here is some historical data on the past post-earnings performance of Pfizer stock compared with the stock performance of peers that reported earnings just before Pfizer. For fair comparison ...

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to ...

Pfizer’s positive comments about the impact of a potential tariff being manageable led the stock to increase despite a softer quarterly performance. Nonetheless, a single quarter’s results are ...

There are instances where high-yielding stocks can simply be great deals. Three stocks that pay at least 6% and don't look ...